Canndoc Overview
Company Headquarters: Herzliya, Israel
Founded: 1994
Workforce: ~200
Company Working: Canndoc is a manufacturer of pharma-grade medical cannabis products for more than 13 years. In September 2018, Canndoc was acquired by InterCure (Israel), a medical device company focused on respiratory treatment; in the last 13 years, the company provided millions of doses to 40,000 patients. It has significant expertise in research, cultivation and processing, product development, and advanced GMP clinical trials pipeline initiation. Canndoc provides Good Manufacturing Practice (GMP) pharma-grade cannabis solutions to the patients for their health and treatment outcomes. Canndoc expanded its global production and distribution capabilities by making commercial agreements and joint ventures in Europe and Canada. Its proprietary genetic bank involves more than thirty unique cannabinoid profiles. The company has a presence in Canada, the UK, Portugal, Denmark, Germany, and Israel.
Strategy
Canndoc has a focus on quality product offerings, with all of its products being GMP-certified. It is expanding its production capabilities and developing a strong distribution network. The company also focusing on research and development activities to develop unique products.
